Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The study will provide additional safety data for specific safety events in persons receiving
intravitreal injections. The Committee for Medicinal Products for Human Use (CHMP) is
interested in obtaining additional safety information when Macugen is used in real world
settings by practitioners in Europe treating patients with neovascular (wet) age-related
macular degeneration (AMD). The study will provide information about physician practice
patterns and characteristics of patients treated with Macugen.